Efficacy and safety of valproic acid in patients with postviral olfactory dysfunctio

Phase 2

• Conditions: postviral olfactory dysfunction

• Registration Number: JPRN-UMIN000019966
• Lead Sponsor: Shiga university of Medical Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-01-01
• Study Completion: 2018-08-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion Criteria concerning Diagnosis 1)Patients taking Carbapenem,Barbituric acid,phenytoin, Carbamazepine, ethosuximide, amitriptyline, clobazam, lamotrigine, salicylic acid, Benzodiazepine, warfarin, erythromycin, cimetidine, clonazepam) 2) Patients having a history of serious drug allergies 3) Patients with severe depression, suicidal thinking or suicide attempt or past history of any of these diseases 4) Patients with liver dysfunction 5) Patients with renal dysfunction 6) Female patients having fertility 7) Patients with urea cycle abnormality 8) Patients with past history of an encephalopathy or a coma caused by unknown 9) Patients having a family member with urea cycle abnormality or who experience infant death 10) Patients with subjective olfactory loss before onset of postviral olfactory dysfunction 11) Patients who are otherwise judged unfit as a subject for this trial by a principal investigator or investigators participating in this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified